PARP-inhibitor on Advanced Metastatic Breast Cancer in Germline PALB2 Mutations Carriers
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer in Germline-PALB2 Mutations Carriers
Interventions: DRUG: Niraparib
Sponsor: Assistance Publique - Hôpitaux de Paris